StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
UPDATE: BioMarin Pharma's (BMRN) First Drisapersen Phase 2 has Issues - FDA Panel
November 24, 2015 3:09 PM
(Updated - November 24, 2015 3:13 PM EST)
BioMarin Pharma (NASDAQ: BMRN) first Kyndrisa (drisapersen) phase 2 ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
FDA
Trader Talk
Trading Halts
Next Articles
BioMarin (BMRN) FDA Panel a 'Drisaster' - Oppenheimer
November 25, 2015 6:46 AM
BioMarin Pharma (BMRN) Receives Unfavorable View from FDA Panel on Kyndrisa as DMD Treatment
November 25, 2015 6:37 AM
BioMarin Pharma (BMRN) dystrophin data don't affect trial results - Bloomberg, Citing FDA Panel
November 24, 2015 5:03 PM
BioMarin Pharma's (BMRN) Drisapersen Phase 2 Issues Don't Affect Findings - FDA Panel
November 24, 2015 3:42 PM
BioMarin Pharma (BMRN) Posts FDA Committee Meeting Presentation on Drisapersen
November 24, 2015 10:05 AM
BioMarin Posts Presentation From FDA Advisory Committee Meeting for Kyndrisa(TM) (drisapersen) for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
November 24, 2015 10:03 AM
Sarepta Therapeutics (SRPT) on Watch as BioMarin's (BMRN) Kyndrisa Adcom Set to Kickoff
November 24, 2015 7:46 AM
BioMarin Pharma (BMRN) Affirms Trading Halt Ahead of FDA Committee Review of Kyndrisa NDA
November 24, 2015 7:08 AM
